Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | NUDT1 | P36639 | 8/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.32 |
| ▸ | DHFR | P00374 | 1/20 | 0.31 |
| ▸ | BRAF | P15056 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29283717 | 0.82 | KDM4E (0.42) | L3MBTL1NUDT1ALDH1A1SMN1; SMN2DHFR | |
| SCHEMBL15177588 | 0.80 | PDK2 (0.36) | L3MBTL1ALDH1A1SMN1; SMN2 | |
| SCHEMBL5021592 | 0.76 | L3MBTL1 (0.35) | L3MBTL1ALDH1A1SMN1; SMN2KCNH2SCN10A | |
| SCHEMBL13122876 | 0.76 | ALDH1A1 (0.31) | L3MBTL1ALDH1A1SMN1; SMN2 | |
| SCHEMBL1644969 | 0.75 | ALDH1A1 (0.38) | NUDT1ALDH1A1SMN1; SMN2 | |
| SCHEMBL29802574 | 0.75 | ALDH1A1 (0.38) | NUDT1ALDH1A1SMN1; SMN2 | |
| SCHEMBL988470 | 0.74 | L3MBTL1 (0.37) | L3MBTL1ALDH1A1SMN1; SMN2KCNH2SCN10A | |
| SCHEMBL2934831 | 0.72 | ADORA2A (0.35) | ALDH1A1 | |
| SCHEMBL5942175 | 0.72 | BCL6 (0.35) | ALDH1A1DHFR | |
| SCHEMBL25377896 | 0.71 | KDM4E (0.38) | ALDH1A1DHFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230143059-A1 | GCN2 MODULATOR COMPOUNDS | Alesta Therapeutics BV (NL) | 2023-05-11 | — | — | US | disclosed |
| US-20230143059-A1 | GCN2 MODULATOR COMPOUNDS | Alesta Therapeutics BV (NL) | 2023-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230143059-A1 | GCN2 MODULATOR COMPOUNDS | EIF2AK4, GPR119, GCN1 | L3MBTL1 2173/4885NUDT1 4028/4885ALDH1A1 4030/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.